Market news

Jazz Pharmaceuticals (NASDAQ:JAZZ) executives outlined the company’s oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the Morgan Stanley Global Healthcare Conference. Chumi Khurana, senior vice president of U.S. Oncology

Jazz Pharmaceuticals (NASDAQ:JAZZ) outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the expansion potential of HER2-targeted therapy Ziihera and ongoing lifecycle work for EPIDIOLEX. Zii

Jazz Pharmaceuticals (JAZZ) has completed its acquisition of privately held Actio Biosciences for $8

Jazz Pharmaceuticals (NasdaqGS:JAZZ) is assessing new trials of newly approved cancer drug Ziihera beyond gastroesophageal adenocarcinoma. The company is preparing development plans to study Ziihera in breast cancer, colorectal cancer, and lung cancer indications. Management is evaluating how broader Ziihera use could reshape Jazz Pharmaceuticals' long term oncology portfolio mix. The move to test Ziihera in breast, colorectal, and lung cancer only captures part of the story for Jazz. We...

Jazz Pharmaceuticals (JAZZ) has an average rating of buy and mean price target of $291.47, according

Jazz Pharmaceuticals (JAZZ) could see long-term value from Ziihera's pursuit of additional indicatio

Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported that Ziihera plus chemotherapy produced a statistically significant and clinically meaningful overall-survival benefit over trastuzumab plus chemotherapy in the Phase 3 HERIZON-GEA-01 trial. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) said the overall-survival hazard ratio improved from the first interim analysis, when the result favored Ziihera but was not statistically significant. The global, […]

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Check out the companies making headlines yesterday:

Jazz up as updated HERIZON-GEA-01 results show statistically significant OS benefits for Ziihera-based regimens in first-line HER2+ gastroesophageal adenocarcinoma.

Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.

Jazz Pharmaceuticals recently secured FDA approval for Ziihera (zanidatamab-hrii)–based regimens in first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma, supported by Phase 3 HERIZON-GEA-01 data showing longer progression-free and overall survival versus trastuzumab plus chemotherapy. This decision materially expands Ziihera’s addressable population beyond previously treated biliary tract cancer and positions Jazz more...

Jazz Pharmaceuticals (JAZZ) has an average rating of buy and mean price target of $291.47, according

Jazz Pharmaceuticals' (JAZZ) shares are up about 45% year to date, but may still have the potential

Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.

Detailed price information for Amneal Pharmaceuticals Inc (AMRX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.

Jazz Pharmaceuticals (JAZZ) said early Thursday it priced its upsized offering of $1.1 billion of 1.

Tipranks Press Release.

Jazz Pharmaceuticals (NASDAQ:JAZZ) outlined its plans for the U.S. launch of Ziihera following FDA approval of the therapy for first-line HER2-positive unresectable, locally advanced or metastatic gastroesophageal adenocarcinoma, or GEA. Ziihera, or zanidatamab, is approved in combination with tisl

Jazz stock bounced off its buy zone Tuesday after the FDA approved its drug, Ziihera, to treat a form of stomach cancer.

Jazz Pharmaceuticals (NASDAQ:JAZZ) has secured FDA approval for two Ziihera-containing regimens in first-line HER2-positive advanced gastroesophageal adenocarcinoma, expanding the drug into an earlier treatment setting after Phase 3 data showed improvements in progression-free and overall survival. Key Investor TakeawaysThe FDA approved Ziihera plus tislelizumab and chemotherapy for first-line treatment of HER2+ advanced GEA patients with IHC 3+ or IHC 2+/ISH+ disease, regardless of PD-L1 status

Jazz Pharmaceuticals (JAZZ) has drawn investor attention after recent share price moves, with the stock closing at $254.28 as of 18 August 2026. This came after modest gains over the past week and year. See our latest analysis for Jazz Pharmaceuticals. For context, the recent 2.24% 1 day share price return builds on a much stronger pattern, with year to date share price gains of 46.86% and a 1 year total shareholder return of 104.09%, signalling firm positive momentum. If Jazz Pharmaceuticals...